IN8bio director awarded 22,000 stock options

IN8BIO, INC. director Peter C. Brandt received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share.

Rhea-AI Filing Summary

IN8BIO, INC. director Peter C. Brandt received a grant of stock options covering 22,000 shares of common stock at an exercise price of $1.58 per share. The options vest in equal monthly installments over 12 months starting on June 9, 2026, and any unvested portion becomes fully vested on the date of the company’s next annual stockholder meeting, subject to continued service. Following this grant, Brandt holds 22,000 stock options directly.

Insider Trade Summary

Grant/Award: 22,000 shares

Grant/Award 1 txn

Insider Brandt Peter C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	22,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,000 contracts (Direct)

Footnotes (1)

1. F1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Key Figures

Options granted: 22,000 options Exercise price: $1.58 per share Post-grant derivative holdings: 22,000 options +2 more

5 metrics

Options granted 22,000 options Stock Option (right to buy) grant to director

Exercise price $1.58 per share Conversion/exercise price for granted options

Post-grant derivative holdings 22,000 options Total derivative securities following transaction

Option expiration date May 9, 2036 Expiration of granted stock options

Vesting commencement June 9, 2026 Start of monthly vesting schedule

Key Terms

Stock Option (right to buy), exercise price, vest in equal monthly installments, annual meeting of stockholders

4 terms

Stock Option (right to buy) financial

"Security title is reported as Stock Option (right to buy)."

exercise price financial

"The conversion or exercise price is stated as $1.5800 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in equal monthly installments financial

"One twelfth of the shares shall vest in equal monthly installments."

annual meeting of stockholders financial

"Options will be fully vested on the date of the Company’s next annual meeting of stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IN8BIO (INAB) report for Peter C. Brandt?

IN8BIO reported that director Peter C. Brandt received a grant of 22,000 stock options. These options give him the right to buy common shares at a fixed exercise price, functioning as equity-based compensation tied to his continued board service.

How many IN8BIO (INAB) stock options were granted to Peter C. Brandt and at what price?

Peter C. Brandt was granted 22,000 stock options with an exercise price of $1.58 per share. This means he can purchase up to 22,000 IN8BIO common shares at $1.58, regardless of the future market price, once the options vest.

What is the vesting schedule for Peter C. Brandt’s IN8BIO (INAB) stock options?

One twelfth of the 22,000 options vests in equal monthly installments starting June 9, 2026. Any remaining unvested options fully vest on the date of IN8BIO’s next annual stockholder meeting, if Brandt continues providing service through each vesting date.

When do Peter C. Brandt’s IN8BIO (INAB) stock options expire?

The granted stock options expire on May 9, 2036. After that expiration date, any unexercised options will no longer be usable, so Brandt must exercise vested options before that deadline if he chooses to acquire the underlying shares.

Does this IN8BIO (INAB) Form 4 show a stock purchase or sale by Peter C. Brandt?

The Form 4 shows an acquisition of stock options as a grant, not an open-market stock purchase or sale. It reflects equity compensation, with no shares of common stock bought or sold in the market in this specific transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brandt Peter C.

(Last) (First) (Middle)

C/O IN8BIO, INC.

350 5TH AVE. SUITE 5330

(Street)

NEW YORK NEW YORK 10118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.58	05/09/2026		A		22,000		(1)	05/09/2036	Common Stock	22,000	$0	22,000	D

Explanation of Responses:

1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

	/s/ William Ho, Attorney-in-Fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)